Showing results (251-260 of 257) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 257 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trialG N Hortobagyi, A Lacko, J Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02S A Hurvitz, S Loi, J O'Shaughnessy, et al.
ESMO Open|May 25, 2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancerK H Park, S Loibl, J Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyN Harbeck, P Rastogi, M Martin, et al.
ESMO Open|September 25, 2025
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)S-A Im, K Park, J Koh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2026
A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY TrialG M Kim, K H Jung, H C Jeung, et al.
Pageof 26